- $1.03bn
- $1.08bn
- $607.91m
- 63
- 65
- 59
- 66
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 403 | 379 | 507 | 625 | 608 |
Cost of Revenue | |||||
Gross Profit | 224 | 196 | 260 | 316 | 313 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 395 | 393 | 488 | 579 | 586 |
Operating Profit | 7.39 | -13.8 | 18.8 | 45.5 | 22.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.6 | -26.2 | 8.87 | 44.5 | 19.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.92 | -29.3 | 13.3 | 28.2 | 84 |
Net Income Before Extraordinary Items | |||||
Net Income | -5.92 | -29.3 | 13.3 | 28.2 | 84 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.92 | -29.3 | 13.3 | 28.2 | 84 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.008 | -0.27 | 0.129 | 0.273 | 0.724 |